May 8, 2025, 03:03

Curebound Equity Grants 2025: $250K to Advance Cancer Research for Underserved Populations

Curebound is accepting Letters of Intent for its 2025 Equity Grants, designed to support up to $250,000 in funding for research that improves cancer care for medically underserved and underrepresented communities. These grants fund projects that examine social, cultural, biological, and systemic barriers while advancing the implementation of effective, equitable care across settings.

Who is eligible?

Applicants must:

Hold an MD, PhD, or equivalent
Be an independent investigator based at one of six San Diego-area institutions:
- UC San Diego (including Moores Cancer Center and UCSD Health)
- Salk Institute
- Sanford Burnham Prebys
- Rady Children’s Hospital
- La Jolla Institute for Immunology
- Scripps Research
Include a Partner PI (optional but encouraged) from a different department or institution
Submit only one LOI per PI for this mechanism

Funding at a glance:

Up to 250,000 USD for one year
Includes direct and indirect costs (indirects capped at 30% of total)
Funds may support salaries (within NIH cap), supplies, reagents, and intervention development
Travel, tuition, and unrelated infrastructure are not allowed

Research focus:

Projects should tackle cancer inequities, including:

Population and implementation science
Interventions to improve access to care or trial participation
Studies of biological differences in cancer outcomes by race, ethnicity, or sex
Equity-focused diagnostics, therapeutics, and preventive strategies
Deployment through hospitals, clinics, digital health tools, or home monitoring

Key deadlines:

Letter of Intent Due: May 5, 2025 (5 PM PDT)
Invitation to Apply: June 17, 2025
Full Proposal Due: July 29, 2025 (5 PM PDT)
Award Notification: December 2025
Project Start Date: January 1, 2026

Where to apply:

Submit via ProposalCentral. Application must include biosketches, project significance, and a clear alignment with Curebound’s research pillars.

Contact:

Program: [email protected]
Tech support: [email protected] | 1-800-875-2562

Cancer Equity cancer innovation cancer outcomes cancer research funding Curebound Equity Grants Health Disparities Implementation Science OncoDaily Oncology population science proposalCENTRAL San Diego research translational research underserved communities

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research